Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs

Patent ExpiryPositive

AI Analysis

Summary

Vesselon received U.S. Patent 12,714,676 for compositions and methods that deliver antibody-based drugs with improved therapeutic index, achieving 6X higher drug concentration in tumors while reducing off-target tissue exposure.

Outcome Details

U.S. Patent Number 12,714,676 issued for compositions and methods for targeted delivery of antibody-based drugs

Importance:5/10

Sentiment:

0.60

patentantibody-drugdrug-deliverytargeted-therapyintellectual-property

Related Companies

$GLSI $CBDY $DMIIR

Read the original article

Published by PR Newswire Clinical Trials on August 26, 2026 4:03 PM

Read Original